Caplin Point Laboratories logo

Caplin Point Laboratories

CAPLIPOINT NSE

Key Fundamentals

SmallcapPharmaceuticalsHealthcare
Market Cap
₹20,690 Cr
Volatility
Moderate
P/E Ratio
31.47
EBITDA
₹876 Cr
Return on Equity
17.89%
Debt to Equity
0.07
Book Value
₹443.33
EPS
₹62.84
52W High
₹2,877.3
52W Low
₹1,500.3

Tapetide Score

Data-driven rating, 0–100. How it works →

Key Insights

Strengths

3
  • Company is almost debt free.
  • Company has delivered good profit growth of 21.4% CAGR over last 5 years
  • Company's median sales growth is 19.9% of last 10 years

Growth Rate

Revenue Growth
13.22% lower than 3Y
Net Income Growth
20.07% higher than 3Y
Cash Flow Change
21.02% lower than 3Y
ROE
-4.59% lower than 3Y
ROCE
-5.91% higher than 3Y
EBITDA Margin (Avg.)
4.13% lower than 3Y

AI Analysis — Bull vs Bear

Anthropic anthropic claude-opus-4.6 2d ago
AI opinion · based on fundamentals
Risk medium

Caplin Point Laboratories is a ₹20,690 Cr market-cap pharmaceutical company that delivered FY25 consolidated revenue of ₹2,034 Cr (up 15.5% YoY) and PAT of ₹541 Cr (up 17.3% YoY), with a virtually debt-free balance sheet and consistent ROE in the 21-23% range. The stock trades at a PE of 31.3x, reflecting a premium valuation relative to its mid-teen revenue growth, while the company is scaling its US injectable business through its subsidiary Caplin Steriles alongside its established Latin America franchise.

Bull Case 8
  • Virtually debt-free balance sheet with free cash reserves of over ₹1,500 Cr and total liquid assets approaching ₹2,875 Cr as of June 2026, providing significant financial flexibility for organic and inorganic growth
  • Consistent profit compounder with 5-year profit CAGR of 21% and 10-year profit CAGR of 30%, demonstrating durable earnings growth across cycles
  • FY25 PAT margin of approximately 26-28% and EBITDA margin of ~37-38% are well above Indian pharma industry averages, reflecting a high-margin product mix and asset-light distribution model in Latin America
  • US injectable business via Caplin Steriles posted ₹366 Cr revenue in FY25 with ₹102 Cr EBITDA, and H1 FY26 US revenue grew 27% YoY to ₹221 Cr, indicating strong ramp-up in the higher-value US market
  • Return on equity has remained consistently above 21% over the last 5 years (5-year average ROE of 23%), indicating efficient capital allocation without leverage
  • 10-year median sales growth of 19.9% and 10-year sales CAGR of 25% demonstrate a long runway of sustained top-line expansion from a low base
  • Stock has delivered a 10-year CAGR of 27% and 3-year CAGR of 42%, significantly outperforming broader market indices over multiple time horizons
  • Growing ANDA portfolio (24+ approved ANDAs as of 2024) with new filings in injectables targeting a US addressable market of $473 Mn, providing optionality for future revenue streams
Bear Case 8
  • PE of 31.3x is a significant premium for a company growing revenue at only 14-16% CAGR over 3-5 years, leaving limited margin of safety if growth decelerates
  • Heavy geographic concentration in Latin America and Francophone Africa exposes the company to currency volatility, regulatory changes, and political instability in emerging markets
  • Q1 FY26 revenue growth decelerated to 11.7% YoY from the 15.5% full-year FY25 growth rate, raising questions about the sustainability of mid-teen growth
  • Gross margin declined from 61.7% in Q1 FY26 to 59.8% in Q1 FY27, suggesting potential margin pressure as product mix shifts or competitive intensity increases
  • Dividend yield of just 0.29% indicates minimal capital return to shareholders despite the strong cash generation, with most value dependent on continued share price appreciation
  • Price-to-book ratio of 6.3x implies the market is pricing in substantial future growth, which increases downside risk if the US sterile injectables business scales slower than expected
  • The US generic injectable market is intensely competitive with pricing erosion, and Caplin Steriles' ₹366 Cr FY25 revenue remains modest relative to established players, creating execution risk
  • TTM revenue growth of 15% and profit growth of 18% show a narrowing gap between top-line and bottom-line growth, suggesting margin expansion may have limited further room

This is AI-generated analysis, not financial advice. Do your own due diligence.

AI News Digest

Anthropic anthropic claude-opus-4.6 2h ago
Headwinds 1
  • USFDA Form 483, 10 observations Aug 24

    Caplin Steriles, a subsidiary, received a USFDA Form 483 with 10 observations during a facility inspection. The company must submit corrective actions to the regulator, posing potential regulatory risk to US market approvals.

Positives 1
  • ₹8/share dividend announced Sep 3

    Caplin Point declared a total dividend of ₹8 per share for FY26, to be approved at the 35th AGM scheduled for September 25, 2026. Signals healthy cash flow and shareholder return commitment.

Neutral 2
  • AGM and board appointments Sep 3

    The 35th AGM is set for September 25, 2026, with key board appointments of Dr. Sridhar Ganesan and Mr. D. Muralidharan on the agenda.

  • FY26 BRSR report filed Sep 3

    Caplin Point filed its Business Responsibility and Sustainability Report for FY26, covering environmental metrics, workforce data, and governance disclosures for the period ending March 31, 2026.

TL;DR: Caplin Point is maintaining steady shareholder returns with an ₹8/share dividend and routine governance filings. The key risk is the USFDA Form 483 with 10 observations at subsidiary Caplin Steriles, which could delay US product approvals if corrective actions are not satisfactory. Overall, the regulatory overhang from the FDA inspection is the primary near-term concern to monitor, while the core business appears stable.

Quarterly Results

Particulars Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Sales
395
410
436
453
459
483
493
502
510
534
543
600
610
Expenses
269
273
293
308
307
318
331
334
332
345
353
396
397
Operating Profit
127
137
142
145
152
165
162
168
178
189
190
204
213
OPM %
32%
34%
33%
32%
33%
34%
33%
33%
35%
35%
35%
34%
35%
Other Income
12
21
17
17
19
21
31
26
23
30
34
28
34
Interest
0
0
0
0
0
0
0
0
0
0
0
0
0
Depreciation
11
12
14
16
16
17
16
17
16
18
19
19
22
PBT
127
146
145
146
154
168
177
177
184
201
204
213
225
Tax %
18%
20%
18%
17%
19%
22%
21%
18%
18%
20%
19%
19%
20%
Net Profit
104
116
120
121
125
131
140
145
151
160
166
173
179
EPS in Rs
13.62
15.13
15.43
16.01
16.31
17.21
18.28
18.76
20.1
20.32
21.56
22.38
23.27
Figures in ₹ Crores

Profit & Loss

Particulars Jun 2015Mar 2016 9mMar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales
252
239
402
540
649
863
1,061
1,269
1,467
1,694
1,937
2,187
2,287
Expenses
192
175
276
345
417
603
732
874
1,025
1,142
1,287
1,422
1,491
Operating Profit
60
64
125
195
232
260
329
395
442
552
651
765
797
OPM %
24%
27%
31%
36%
36%
30%
31%
31%
30%
33%
34%
35%
35%
Other Income
3
4
10
13
19
41
23
38
55
66
92
111
126
Interest
1
0
1
1
1
0
2
1
1
1
1
1
1
Depreciation
8
7
13
19
23
32
37
47
45
53
66
73
78
PBT
53
60
121
188
227
269
314
386
451
564
677
803
844
Tax %
23%
24%
21%
23%
22%
20%
20%
20%
16%
18%
20%
19%
—
Net Profit
41
46
96
145
177
215
251
308
377
461
541
650
678
EPS in Rs
5.43
6.05
12.65
19.15
23.35
28.42
32.03
39.56
49.57
60.19
70.56
84.36
87.53
Div. Payout %
18%
20%
12%
10%
9%
9%
9%
10%
9%
8%
8%
9%
—
Figures in ₹ Crores

Balance Sheet

Particulars Jun 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital
15
15
15
15
15
15
15
15
15
15
15
15
Reserves
78
113
210
349
582
858
954
1,252
1,649
2,084
2,619
3,355
Borrowings
2
2
1
1
36
113
235
219
222
219
222
221
Other Liabilities
134
137
133
136
109
139
159
250
305
380
352
446
Total Liabilities
229
267
358
500
743
1,126
1,364
1,736
2,191
2,698
3,208
4,038
Fixed Assets
113
144
152
169
227
272
305
287
280
453
546
580
CWIP
31
0
3
15
10
20
14
18
221
117
144
234
Investments
0
0
17
47
70
61
11
89
281
376
590
859
Other Assets
85
122
186
269
436
772
1,033
1,343
1,410
1,753
1,928
2,365
Total Assets
229
267
358
500
743
1,126
1,364
1,736
2,191
2,698
3,208
4,038
Figures in ₹ Crores

Cash Flow

Particulars Jun 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating
50
42
68
66
83
45
269
337
271
318
432
523
Investing
-23
-6
-36
-69
-100
-54
-30
-377
-216
-319
-333
-582
Financing
-9
-14
-7
-12
90
80
-24
-41
-28
-38
-38
-46
Net Cash Flow
19
23
25
-14
73
70
215
-81
27
-39
61
-105
Free Cash Flow
24
34
43
18
18
-32
195
246
78
173
241
275
CFO/OP
103
92
73
53
54
38
102
106
81
77
86
87
Figures in ₹ Crores

Ratios

Particulars Jun 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days
8
12
30
85
90
97
96
91
98
117
119
138
Inventory Days
37
57
44
44
47
210
139
149
159
183
159
181
Days Payable
112
168
155
144
76
57
68
102
84
116
103
125
Cash Conversion Cycle
-67
-99
-81
-16
61
251
166
138
173
184
175
194
Working Capital Days
-128
-114
-29
47
104
167
145
165
144
166
174
199
ROCE %
68%
62%
68%
63%
45%
33%
28%
28%
26%
26%
26%
24%

Insights

Beta

AI-extracted from concalls & annual reports · figures as reported, with sources

Log in to view Caplin Point Laboratories insights

70 extracted metrics + investor summaries across FY11–FY26.

Log in — free

Shareholding Pattern

DIIs2.49%Promot.70.57%FIIs5.75%Others6.56%Public14.62%As ofJun 2026

Documents

Frequently Asked Questions about Caplin Point Laboratories

What does Caplin Point Laboratories Ltd do?
Caplin Point Laboratories Ltd is engaged in the manufacturing and sourcing of APIs, finished formulations, R&D, clinical research with presence in Latin America, Africa, USA and other nations.[1]
Where is Caplin Point Laboratories Ltd (CAPLIPOINT) listed?
Caplin Point Laboratories Ltd trades as CAPLIPOINT on the NSE and under code 524742 on the BSE.
Which sector does Caplin Point Laboratories Ltd belong to?
Caplin Point Laboratories Ltd is classified under the Healthcare sector, in the Pharmaceuticals industry.
What is the market capitalisation of Caplin Point Laboratories Ltd?
Caplin Point Laboratories Ltd has a market capitalisation of ₹20,690 Cr, which places it in the Large Cap band.
What is the PE ratio of Caplin Point Laboratories Ltd?
Caplin Point Laboratories Ltd trades at a PE ratio of 31.47, on earnings per share of ₹62.84, against a book value of ₹443.33 per share.
What is the 52-week high and low of Caplin Point Laboratories Ltd?
Over the last 52 weeks Caplin Point Laboratories Ltd has traded between ₹1,500.3 and ₹2,877.3.
Does Caplin Point Laboratories Ltd pay dividends?
Caplin Point Laboratories Ltd has a dividend yield of 0.29%.
What is the Return on Equity (ROE) of Caplin Point Laboratories Ltd?
Caplin Point Laboratories Ltd reported a return on equity of 17.89%. Its debt-to-equity ratio is 0.07.

Company Information

Caplin Point Laboratories Ltd is engaged in the manufacturing and sourcing of APIs, finished formulations, R&D, clinical research with presence in Latin America, Africa, USA and other nations.[1]

Website caplinpoint.net
CEO Dr. Sridhar Ganesan
Employees 3,966
Listed 1994-11-16
Face Value ₹ 2
Issued Size 7,60,11,696

For AI agents and developers

Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/CAPLIPOINT.md for Caplin Point Laboratories Ltd: company profile, latest price, key fundamentals, the Tapetide Score, growth rates, quarterly and annual financial statements, shareholding pattern, technical indicators, analyst ratings and exchange filings.

Append .md to any Tapetide URL for the same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For live, structured queries instead of documents, use our MCP server.

Explore More

More in Healthcare → FII DII Data Stock Screener Nifty 50 Heatmap F&O Ban List